Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases.

ABSTRACT: Treatment guidelines provided by PRODIGE-7 recommend perioperative systemic chemotherapy before cytoreductive surgery (CRS) for colorectal cancer peritoneal metastases (CRPM). Toxicity with multimodal treatment needs to be better defined. Chemotherapy response and impact on survival have not been reported. We assessed CRPM patients who received systemic oxaliplatin/irinotecan before CRS (preoperative) with Mitomycin C (35 mg/m², 90 min) or Oxaliplatin (368 mg/m², 30 min) heated intraperitoneal chemotherapy (HIPEC). Secondary analysis was performed from a prospective database. Overall survival (OS) in chemotherapy responders (R) and nonresponders (NR) was compared. Toxicity was assessed by rate of adverse events (AEs). From April 2005 to April 2021, 436 patients underw

SUBMITTER: Tinsley N 

PROVIDER: S-EPMC11826003 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature